# Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome

> **NCT01294878** · PHASE3 · COMPLETED · sponsor: **Fondazione IRCCS Policlinico San Matteo di Pavia** · enrollment: 3 (actual)

## Conditions studied

- Interstitial Cystitis
- Painful Bladder Syndrome

## Interventions

- **DRUG:** omalizumab

## Key facts

- **NCT ID:** NCT01294878
- **Lead sponsor:** Fondazione IRCCS Policlinico San Matteo di Pavia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03
- **Primary completion:** 2010-09
- **Final completion:** 2010-10
- **Target enrollment:** 3 (ACTUAL)
- **Last updated:** 2011-02-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01294878

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01294878, "Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01294878. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*